文献速递主动脉疾病

腹主动脉内移植物感染的外科治疗结局:双中心回顾性研究

Surgical Treatment Outcomes of Abdominal Aortic Endograft Infection: A Dual-Center Retrospective Study.
PubMed 文献 · Ann Vasc Surg · 2026-06-24

该双中心回顾性队列纳入41例腹主动脉内移植物感染(AAEI)患者,均行感染移植物完整切除并血运重建,39例采用解剖外旁路(EAB)、2例原位重建。中位随访12个月,全因死亡率29.3%,非致命并发症率39.0%,再干预率17.1%(7/41)。术前白细胞升高(P=0.01,HR=3.90)和肠瘘(P=0.04,HR=3.21)与生存恶化相关,高龄呈显著性趋势(P=0.09)。

要点

  • EAB是高风险AAEI患者可行且实用的血运重建选择,尤其适用于缺乏生物移植物的中心。
  • 肠瘘和术前白细胞升高是生存不良的预测因素,高龄呈显著性趋势。
  • AAEI术后全因死亡率29.3%、非致命并发症率39.0%、再干预率17.1%。

核心结论

  • EAB是高风险AAEI患者可行且实用的选择,尤其适用于缺乏生物移植物的中心。
  • 肠瘘、术前白细胞升高和高龄预测生存不良。
  • 需要大型前瞻性多中心试验来完善AAEI的个体化治疗。

研究设计与样本

  • 双中心回顾性队列研究,纳入2018年2月至2025年9月期间接受感染移植物完整切除和血运重建的41例AAEI患者。
  • 采用Kaplan-Meier生存分析和单因素COX回归分析临床数据。

主要发现

  • 队列包括40例男性和1例女性,平均年龄64.22±9.12岁。
  • 所有病例均完整切除感染移植物,血运重建通过解剖外旁路(EAB,n=39)或原位重建(n=2)实现。
  • 中位随访时间12个月,全因死亡率29.3%,非致命并发症率39.0%,再干预率17.1%(7/41)。
  • 术前白细胞升高(P=0.01,HR=3.90)和肠瘘(P=0.04,HR=3.21)与生存恶化相关;高龄呈显著性趋势(P=0.09)。
  • C反应蛋白水平和肾动脉支架覆盖对预后无显著影响(P>0.05)。

关键数值与推荐

  • 全因死亡率29.3%,非致命并发症率39.0%,再干预率17.1%(7/41)。
  • 术前白细胞升高:P=0.01,HR=3.90;肠瘘:P=0.04,HR=3.21;高龄:P=0.09。
  • C反应蛋白水平和肾动脉支架覆盖:P>0.05。

临床怎么用

  • 对于高风险AAEI患者,EAB可作为缺乏生物移植物中心的可行的血运重建选择。
  • 术前应关注白细胞升高和肠瘘,以识别生存预后不良的高风险患者。
  • 高龄患者可能需更谨慎的个体化治疗决策。

局限性

  • 回顾性研究设计。
  • 样本量较小(41例)。
  • 随访时间有限(中位12个月)。
  • 单因素分析可能无法排除混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abdominal aortic endograft infection (AAEI) is a rare but life-threatening complication following endovascular aneurysm repair. This study aimed to report surgical outcomes of AAEI from 2 specialized Chinese vascular centers and analyze prognostic risk factors. METHODS: A dual-center retrospective cohort study enrolled 41 patients who underwent complete infected graft excision and revascularization for AAEI between February 2018 and September 2025. Clinical data were collected and analyzed via Kaplan-Meier survival analysis and univariate COX regression. RESULTS: This cohort included 40 males and 1 female (mean age: 64.22 ± 9.12 years). Complete removal of the infected graft was performed in all cases, with revascularization achieved via extra-anatomical bypass (EAB, n = 39) or in situ reconstruction (n = 2). Median follow-up time was 12 months. All-cause mortality was 29.3%, nonfatal complication rate was 39.0% and reintervention rate was 17.1% (7/41). Elevated white blood cell (WBC) (P = 0.01, hazard ratio [HR] = 3.90) and enteric fistula (P = 0.04, HR = 3.21) worsened survival; advanced age showed a trend toward significance (P = 0.09). C-reactive protein level and renal artery stent coverage had no significant prognostic impact (P > 0.05). CONCLUSION: EAB is a feasible and practical option for high-risk AAEI patients, particularly at centers lacking biological grafts. Enteric fistula, elevated preoperative WBC, and advanced age predict poor survival. Large prospective multicenter trials are needed to refine individualized treatments for AAEI.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang X, Diao Y, Qi B, et al. Surgical Treatment Outcomes of Abdominal Aortic Endograft Infection: A Dual-Center Retrospective Study. Ann Vasc Surg. 2026. PMID: 42342213. doi:10.1016/j.avsg.2026.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。